KLRK1 and B-cell chronic lymphocytic leukemia: The same potentiated effect was observed on PBMCs derived from CLL patients, which, in line with previously published data, showed a dysfunctionality of CLL-NK cells with a reduction in NK-mediated direct cytotoxicity (specifically measured with K562 target population) and expression of the activating receptor NKG2D in NK cells.